Kezar Life Sciences, Inc. to Post FY2023 Earnings of ($1.27) Per Share, Jefferies Financial Group Forecasts (NASDAQ:KZR)

Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) – Investment analysts at Jefferies Financial Group issued their FY2023 EPS estimates for Kezar Life Sciences in a report issued on Tuesday, March 14th. Jefferies Financial Group analyst M. Raycroft anticipates that the company will earn ($1.27) per share for the year. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.15) per share. Jefferies Financial Group also issued estimates for Kezar Life Sciences’ FY2024 earnings at ($1.42) EPS, FY2025 earnings at ($1.54) EPS and FY2026 earnings at ($1.49) EPS.

KZR has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Kezar Life Sciences in a report on Thursday. Wells Fargo & Company decreased their price target on shares of Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, January 3rd. Finally, William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday.

Kezar Life Sciences Trading Down 1.6 %

Kezar Life Sciences stock opened at $3.76 on Friday. The stock has a market cap of $266.22 million, a P/E ratio of -3.72 and a beta of 0.25. Kezar Life Sciences has a fifty-two week low of $3.55 and a fifty-two week high of $18.55. The firm’s fifty day moving average price is $6.21 and its 200-day moving average price is $7.26. The company has a debt-to-equity ratio of 0.04, a quick ratio of 31.15 and a current ratio of 25.98.

Insider Buying and Selling

In other Kezar Life Sciences news, major shareholder Morningside Venture Investment sold 40,000 shares of the firm’s stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $6.88, for a total transaction of $275,200.00. Following the completion of the transaction, the insider now owns 5,447,993 shares of the company’s stock, valued at $37,482,191.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 248,276 shares of company stock valued at $1,708,683 over the last three months. Corporate insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Kezar Life Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its position in shares of Kezar Life Sciences by 8.3% during the 4th quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $135,000 after purchasing an additional 1,461 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Kezar Life Sciences by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 140,148 shares of the company’s stock worth $987,000 after purchasing an additional 1,608 shares during the period. The Manufacturers Life Insurance Company boosted its position in Kezar Life Sciences by 11.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 20,633 shares of the company’s stock valued at $145,000 after buying an additional 2,040 shares during the period. Dimensional Fund Advisors LP boosted its position in Kezar Life Sciences by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 277,928 shares of the company’s stock valued at $4,619,000 after buying an additional 2,130 shares during the period. Finally, Arizona State Retirement System raised its holdings in shares of Kezar Life Sciences by 17.5% in the 4th quarter. Arizona State Retirement System now owns 14,469 shares of the company’s stock valued at $102,000 after purchasing an additional 2,156 shares in the last quarter. Hedge funds and other institutional investors own 84.03% of the company’s stock.

Kezar Life Sciences Company Profile

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.